Atrium Therapeutics, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
7.66
-0.01 (-0.13%)
Oct 19, 2026, 3:49 PM EDT - Market open
Atrium Therapeutics Revenue
In the year 2025, Atrium Therapeutics had annual revenue of $18.76M with 72.11% growth. Atrium Therapeutics had revenue of $860.00K in the quarter ending December 31, 2025, a decrease of -71.07%. That makes Atrium Therapeutics the 30,236th largest company in the world by revenue and 4,014th in the United States.
Revenue (ttm)
$18.76M
Revenue Growth
+72.11%
P/S Ratio
3.66
Revenue / Employee
n/a
Employees
n/a
Market Cap
131.03M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 18.76M | 7.86M | 72.11% |
| Dec 31, 2024 | 10.90M | 1.34M | 13.99% |
| Dec 31, 2023 | 9.56M | 336.00K | 3.64% |
| Dec 31, 2022 | 9.22M | -102.00K | -1.09% |
| Dec 31, 2021 | 9.33M | 2.54M | 37.41% |
| Dec 31, 2020 | 6.79M | 4.47M | 192.67% |
| Dec 31, 2019 | 2.32M | 1.94M | 511.87% |
| Dec 31, 2018 | 379.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 77.68M |
| Innate Pharma | 11.21M |
| Adagene | 9.29M |
| Armata Pharmaceuticals | 5.54M |
| Korro Bio | 2.38M |
RNA News
- 11 days ago - Atrium Therapeutics announces $50M private placement - TheFly
- 11 days ago - Atrium Therapeutics Announces $50 Million Private Placement - PRNewsWire
- 27 days ago - Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 6 weeks ago - Atrium Therapeutics to Participate in Upcoming Investor Conferences - PRNewsWire
- 1 month ago - Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 2 months ago - Atrium Therapeutics earns $15M milestone payment from Bristol Myers - TheFly
- 2 months ago - Atrium Therapeutics reports Q2 EPS ($1.18) vs (75c) last year - TheFly
- 2 months ago - Atrium Therapeutics Reports Second Quarter 2026 Financial Results - PRNewsWire